148182 20250114175434.0 doi 10.1016/j.arteri.2020.12.006 sideral 126621 ART-2021-126621 spa Marco-Benedí V. Carga de enfermedad. Cálculo del riesgo cardiovascular y objetivos terapéuticos 2021 Therapeutic intervention should be determined by the risk of developing atheromatous cardiovascular disease (CVD). The higher the risk, the more intense the action should be. This is the reason for the stratification of patient risk. In primary prevention, the two main guidelines used, the American Heart Association and the American College of Cardiology (ACC/AHA) use the Pooled cohort equations (PCE) and the guidelines of the European societies use the SCORE tables. The PCE calculates the risk of fatal and non-fatal CVD, and the SCORE calculates risk of fatal CVD only. In young people, it is useful to consider the lifetime risk calculation. The Spanish Society of Arteriosclerosis (SEA) recommends the SCORE system in Spain. SCORE and PCE calculate the risk for people up to 70 and 75 years of age. Prediction and potentials are available for 80 years of age and above, with the data available being much more scarce. Risk stratification in secondary prevention may be useful to identify the subgroup of patients who may benefit from more intensive treatment. Imaging tests, especially coronary calcium scans and vascular ultrasound, can help to better the profile risk. European guidelines identify LDL cholesterol as a therapeutic target. They recommend initiating treatment with statins, and increasing dose and potency until targets are achieved, and then to treatment with potent statins at a maximum tolerated dose, and ezetimibe if targets are not achieved. As a third step, PCSK9 inhibitors are indicated. They set very ambitious targets, as low as 40 mg/dL in those subjects with recurrences before two years of CVD despite high-intensity statin therapy, and below 55 mg/dL for all very high-risk subjects. © 2021 Sociedad Española de Arteriosclerosis Access copy available to the general public Unrestricted info:eu-repo/semantics/openAccess by-nc-nd http://creativecommons.org/licenses/by-nc-nd/3.0/es/ 0.325 2021 Pharmacology (medical) 2021 Q3 Cardiology and Cardiovascular Medicine 2021 Q3 2.1 2021 info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion Jarauta Simón E. Universidad de Zaragoza (orcid)0000-0001-9142-0737 Laclaustra Gimeno M. Universidad de Zaragoza (orcid)0000-0003-3963-0846 Civeira Murillo F. Universidad de Zaragoza (orcid)0000-0001-7043-0952 1007 610 Universidad de Zaragoza Dpto. Medicina, Psiqu. y Derm. Area Medicina 33 (2021), 10-17 Clín. investig. arterioscler. Clinica e Investigacion en Arteriosclerosis 0214-9168 610252 http://zaguan.unizar.es/record/148182/files/texto_completo.pdf Versión publicada 2057861 http://zaguan.unizar.es/record/148182/files/texto_completo.jpg?subformat=icon icon Versión publicada oai:zaguan.unizar.es:148182 articulos driver 2025-01-14-15:49:00 ARTICLE